RxDoctor Payments Data

Tiffany Randazzo

Gerontology · Manhasset, NYNPI 1144738543

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 37.0% of the total.

$689in general payments, 2019–2025

Across 30 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$254
  • Teleflex LLC$131
  • Axonics, Inc.$82
  • Antares Pharma, Inc.$61
  • 180 Medical, Inc.$27
  • Coloplast$25
  • plus $108 from 6 others

What the payments were for

  • Food & beverage$689100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$689 in reported general payments places this provider in the 70th percentile of 187 gerontology providers in New York.

See all gerontology providers in New York

Medicare billing

Part B allowed, 2024
$169,723
Medicare patients
256
Services billed
2,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate75$448,801
GemtesaVibegron156$136,125
MyrbetriqMirabegron142$125,075
Tamsulosin Hcl900$14,677
Oxybutynin Chloride ErOxybutynin Chloride243$5,174
Testosterone22$4,661
Finasteride299$2,826
Tadalafil11$2,575
Alfuzosin Hcl ErAlfuzosin Hcl100$2,223
Tolterodine Tartrate ErTolterodine Tartrate30$2,172
Trospium Chloride35$1,991
Dutasteride69$1,780
CefuroximeCefuroxime Axetil155$1,536
Solifenacin Succinate20$1,320
Testosterone Cypionate57$1,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$17$448,80175 claims
Sumitomo Pharma America, Inc.Gemtesa$17$136,125156 claims
Astellas Pharma US IncMyrbetriq$254$125,075142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 gerontology providers in New York.

Other gerontology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →